...
首页> 外文期刊>BMC Infectious Diseases >Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls
【24h】

Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls

机译:Rv1985c,一种有前途的新型抗原,可用于从卡介苗接种的对照中诊断结核感染

获取原文

摘要

Background Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific antigens for immunodiagnosis. In the present study, recombinant protein Rv1985c from RD2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (TB) infection among BCG-vaccinated individuals. Methods T-cell response to Rv1985c was evaluated by IFN-γ ELISPOT in 56 TB patients, 20 latent TB infection (LTBI) and 30 BCG-vaccinated controls in comparison with the commercial T-SPOT. TB kit. Humoral response was evaluated by ELISA in 117 TB patients, 45 LTBI and 67 BCG-vaccinated controls, including all those who had T-cell assay, in comparison with a commercial IgG kit. Results Rv1985c was specifically recognized by cellular and humoral responses from both TB and LTBI groups compared with healthy controls. Rv1985c IgG-ELISA achieved 52% and 62% sensitivity respectively, which outperformed the sensitivity of PATHOZYME-MYCO kit (34%) in detecting active TB (P = 0.011), whereas IFN-γ Rv1985c-ELISPOT achieved 71% and 55% sensitivity in detecting active and LTBI, respectively. Addition of Rv1985c increased sensitivities of ESAT-6, CFP-10 and ESAT-6/CFP-10 combination in detecting TB from 82.1% to 89.2% (P = 0.125), 67.9% to 87.5% (P < 0.001) and 85.7% to 92.9% (P = 0.125), respectively. Conclusions In conclusion, Rv1985c is a novel antigen which can be used to immunologically diagnose TB infection along with other immunodominant antigens among BCG-vaccinated population.
机译:背景结核分枝杆菌差异区(RD)中编码的抗原构成了用于免疫诊断的特定抗原的潜在来源。在本研究中,来自RD2的重组蛋白Rv1985c被克隆,表达,纯化,免疫学表征并研究了其对BCG疫苗接种个体中结核(TB)感染的潜在诊断价值。方法与商用T-SPOT相比,通过IFN-γELISPOT评价了56 TB患者,20例潜伏性结核感染(LTBI)和30例接种BCG的对照组对Rv1985c的T细胞反应。 TB套件。与商用IgG试剂盒相比,通过ELISA对117 TB患者,45例LTBI和67例BCG接种的对照(包括所有进行T细胞分析的对照)进行了体液反应评估。结果与健康对照组相比,TB和LTBI组的细胞和体液反应都能特异性识别Rv1985c。 Rv1985c IgG-ELISA分别达到52%和62%的灵敏度,超过PATHOZYME-MYCO试剂盒在检测活动性TB时的灵敏度(34%)(P = 0.011),而IFN-γRv1985c-ELISPOT的灵敏度则达到71%和55%。分别检测主动和LTBI。添加Rv1985c可将ESAT-6,CFP-10和ESAT-6 / CFP-10组合检测结核病的敏感性从82.1%提高到89.2%(P = 0.125),67.9%提高到87.5%(P <0.001)和85.7%分别达到92.9%(P = 0.125)。结论总之,Rv1985c是一种新型抗原,可用于在BCG接种人群中与其他免疫显性抗原一起免疫诊断结核感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号